Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.

Machado M, Lopera MM, Diaz-Rojas J, Jaramillo LE, Einarson TR; Universidad Nacional de Colombia Pharmacoeconomics Group.

Rev Panam Salud Publica. 2008 Oct;24(4):233-9.

PMID:
19133171
2.
3.
4.

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.

Lenox-Smith A, Greenstreet L, Burslem K, Knight C.

Clin Drug Investig. 2009;29(3):173-84. doi: 10.2165/00044011-200929030-00004. Erratum in: Clin Drug Investig. 2010;30(1):70.

PMID:
19243210
5.

Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.

Einarson TR, Addis A, Iskedjian M.

Pharmacoeconomics. 1997 Aug;12(2 Pt 2):286-96.

PMID:
10170453
6.
7.

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.

van Baardewijk M, Vis PM, Einarson TR.

Curr Med Res Opin. 2005 Aug;21(8):1271-9.

PMID:
16083537
8.
9.

Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.

Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE.

J Clin Psychiatry. 1997 Feb;58(2):47-58.

PMID:
9062373
10.

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.

Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, Panish JM.

J Clin Psychopharmacol. 2004 Oct;24(5):497-506.

PMID:
15349005
11.
12.

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.

Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F.

Int Clin Psychopharmacol. 2000 Jan;15(1):29-34. Erratum in: Int Clin Psychopharmacol 2000 Mar;15(2):120.

PMID:
10836283
13.

Pharmacoeconomic studies of antidepressants: focus on venlafaxine.

Woods SW.

Depress Anxiety. 2000;12 Suppl 1:102-9. Review.

PMID:
11098423
14.

Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.

Serrano-Blanco A, Gabarron E, Garcia-Bayo I, Soler-Vila M, Caramés E, Peñarrubia-Maria MT, Pinto-Meza A, Haro JM; Depressió en Atenció Primària de Gavà Group (D. A. P. G. A.).

J Affect Disord. 2006 Apr;91(2-3):153-63. Epub 2006 Feb 3.

PMID:
16458976
15.
16.

Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.

Bosmans JE, Hermens ML, de Bruijne MC, van Hout HP, Terluin B, Bouter LM, Stalman WA, van Tulder MW.

J Affect Disord. 2008 Nov;111(1):106-12. doi: 10.1016/j.jad.2008.02.002. Epub 2008 Mar 14.

PMID:
18342952
17.

[Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].

Baca Baldomero E, Rubio-Terrés C.

Actas Esp Psiquiatr. 2006 May-Jun;34(3):193-201. Review. Spanish.

PMID:
16736393
18.

One-year costs of second-line therapies for depression.

Sullivan EM, Griffiths RI, Frank RG, Strauss MJ, Herbert RJ, Clouse J, Goldman HH.

J Clin Psychiatry. 2000 Apr;61(4):290-8.

PMID:
10830151
19.

Economic appraisal of citalopram in the management of single-episode depression.

Sclar DA, Skaer TL, Robison LM, Galin RS.

J Clin Psychopharmacol. 1999 Oct;19(5 Suppl 1):47S-54S.

PMID:
10507508
20.

Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.

Russell JM, Berndt ER, Miceli R, Colucci S, Grudzinski AN.

Am J Manag Care. 1999 May;5(5):597-606.

Supplemental Content

Support Center